VascularStrategies
Private Company
Funding information not available
Overview
Founded in 2015 and based in Minneapolis, VascularStrategies operates as a contract research organization (CRO) serving the cardiovascular therapeutics sector. Its core business is providing cutting-edge research services to biopharma clients developing drugs that target atherosclerosis through mechanisms like HDL function and reverse cholesterol transport. The company leverages a specialized technology platform combining in vitro and in vivo models to de-risk and accelerate partner programs. As a private, likely pre-revenue or early-revenue services firm, its success is tied to its scientific reputation and the progression of its clients' pipelines.
Technology Platform
Integrated suite of in vitro and in vivo assays focused on lipoprotein function, HDL biology, Reverse Cholesterol Transport (RCT), and immune mediators in atherosclerosis. Platform includes functional HDL testing and animal models for plaque regression studies.
Opportunities
Risk Factors
Competitive Landscape
VascularStrategies competes within the broader contract research organization (CRO) market, but its direct competitors are likely other specialized labs and academic cores offering similar lipoprotein and cardiovascular disease model services. It differentiates through a dedicated focus on integrated in vitro/in vivo atherosclerosis regression models. Larger, full-service CROs offer broader capabilities but may lack this specific depth of expertise.